Amena Iqbal
Endocrinology, Diabetes & Metabolism · Saint Joseph, MINPI 1124469523
Payments from drug & device makers
Across 510 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Xeris Pharmaceuticals, Inc.$544
- Lilly USA, LLC$511
- Tandem Diabetes Care, Inc.$452
- Amgen$438
- AstraZeneca$415
- plus $4K from 34 others
What the payments were for
- Food & beverage$7,51899%
- Education$441%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 133 | $1,450 |
| Xeris Pharmaceuticals, Inc. | 30 | $544 |
| Lilly USA, LLC | 41 | $511 |
| Tandem Diabetes Care, Inc. | 27 | $452 |
| Amgen(2 entities) | 25 | $438 |
| AstraZeneca(2 entities) | 24 | $415 |
| Insulet Corporation | 30 | $370 |
| Dexcom, Inc. | 19 | $333 |
| Corcept Therapeutics | 17 | $287 |
| Johnson & Johnson | 19 | $270 |
| Novartis | 18 | $264 |
| Bayer | 16 | $247 |
| AbbVie | 13 | $243 |
| Sanofi-aventis U.S. LLC | 13 | $222 |
| Boehringer Ingelheim | 12 | $197 |
| Amneal Pharmaceuticals LLC | 6 | $118 |
| Medtronic(2 entities) | 8 | $117 |
| Recordati_rare_diseases_inc. | 5 | $109 |
| Abbott | 5 | $99 |
| Amarin Pharma, Inc. | 5 | $92 |
| GSK | 5 | $86 |
| Shire North American Group Inc | 4 | $77 |
| Antares Pharma, Inc. | 5 | $75 |
| Ascendis Pharma Endocrinology Inc | 4 | $75 |
| Radius Health, Inc. | 4 | $71 |
| Merck | 4 | $63 |
| Ipsen Biopharmaceuticals, Inc | 3 | $56 |
| Madrigal Pharmaceuticals | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Globus Medical | 1 | $30 |
| Alfasigma USA, Inc. | 1 | $23 |
| Pfizer | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| EUSA Pharma (US) LLC | 1 | $19 |
| Nalpropion Pharmaceuticals LLC | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
How this compares
$7,562 in reported general payments places this provider in the 70th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 697 | $813,247 |
| OzempicSemaglutide | 353 | $415,778 |
| JardianceEmpagliflozin | 298 | $289,934 |
| Humalog Kwikpen U-200Insulin Lispro | 113 | $221,215 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 81 | $150,278 |
| FarxigaDapagliflozin Propanediol | 137 | $133,057 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 151 | $121,011 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $113,559 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 104 | $93,865 |
| TrulicityDulaglutide | 72 | $85,375 |
| Tresiba Flextouch U-100Insulin Degludec | 107 | $81,417 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $59,342 |
| CreonLipase/Protease/Amylase | 20 | $51,594 |
| Novolog FlexpenInsulin Aspart | 109 | $35,579 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $30,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $511 | $914,907823 claims |
| Novo NordiskOzempic, Wegovy, Xultophy 100-3.6, Novolog | $1,450 | $467,153411 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $197 | $353,111356 claims |
| AstraZenecaFarxiga | $415 | $133,057137 claims |
| AbbVieCreon, Synthroid | $243 | $66,340247 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $118 | $5,696601 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Saint Joseph
- Amanda MorrisSaint Joseph$13K
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.